Shares of Australian specialty pharma firm Mayne Pharma Group (ASX: MYX) closed up 9.2% at A$3.68 today, after it released full-year fiscal 2023 financials, showing that reported revenues were A$183.6 million (US$118.5 million), up 17% on FY 2022.Reported gross profit was also up 17% at A$83.5 million, with net loss after tax coming in at A$317.4 million, compared with A$220.1 million the previous yearMayne says it has successfully refocused the company around core businesses with the exclusive US license to a portfolio of on-market women’s health products - Annovera (segesterone acetate/ethinyl estradiol), Imvexxy (segesterone acetate/ethinyl estradiol), Bijuva (estradiol and progesterone capsules) – acquired from TherapeuticsMD (Nasdaq: TXMD), as well as pre-natal vitamins. Also contributing was the sale of Metrics Contract Services (MCS) and US Retail GenericsContinued revenue growth of Branded Products was noted, at A$61.9 million in FY 2023 versus A$10.6 million FY 2022 (up 484%) and International A$64.7 million, up 19%. Portfolio products rebounded in the second half of the year, with second half 20223 revenue up 313% from first half 2023.
Shares of Australian specialty pharma firm Mayne Pharma Group...
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.10 |
Change
-0.560(8.41%) |
Mkt cap ! $518.9M | |||
| Open | High | Low | Value | Volume |
| $6.62 | $6.62 | $6.10 | $1.789M | 285.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 721 | $6.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.10 | 768 | 1 |
View Market Depth
| Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$6.14 |
Change
-0.560 ( 7.59 %) |
||||
| Open | High | Low | Volume | ||
| $6.55 | $6.58 | $6.13 | 66128 | ||
| Last updated 15.59pm 15/05/2024 ? | |||||
| MYX (ASX) Chart |